Hsuan-Yu Peng1, Ming-Chu Chang1,2, Chun-Mei Hu3, Hwai-I Yang3, Wen-Hwa Lee3,4, Yu-Ting Chang5,6. 1. Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. 2. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. 3. Genomics Research Center, Academia Sinica, Taipei, Taiwan. 4. Taiwan Graduate Institute of Clinical Medicine, China Medical University, Taichung, Taiwan. 5. Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. yutingchang@ntu.edu.tw. 6. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. yutingchang@ntu.edu.tw.
Abstract
BACKGROUND: Thrombospondin-2 (TSP-2) has been reported as an early diagnostic marker for pancreatic ductal adenocarcinoma (PDAC) in Caucasian populations. This study was designed to validateTSP-2 as a diagnostic marker in a large Taiwan cohort and to investigate the association of TSP-2 with the clinical outcomes of PDAC patients. METHODS: The serum TSP-2 levels in 263 PDAC patients and 230 high-risk individuals (HRIs) were measured via an enzyme-linked immunosorbent assay. The sensitivity, specificity, and accuracy of TSP-2 as a diagnostic marker to discriminating PDAC patients from HRIs and correlations between TSP-2 levels and prognosis of PDAC patients were analyzed. RESULTS: Serum TSP-2 levels were significantly higher in patients with PDAC (44.90 ± 40.70 ng/ml) than in the HRIs (17.52 ± 6.23 ng/ml). At a level of ≥ 29.8 ng/ml, TSP-2 exhibited 100% specificity, 55.9% sensitivity, 100% positive predictive value (PPV), and 66.5% negative predictive value (NPV) for discriminating PDAC patients from HRIs. The Cox regression analysis showed that higher serum TSP-2 levels were significantly associated with poor outcomes in PDAC patients (hazard ratio = 1.54, 95% confidence interval = 1.143-2.086, P = 0.005). Combining the carbohydrate antigen 19-9 (CA19-9) (cutoff value of 62.0 U/ml) and TSP-2 (cutoff value of 29.8 ng/ml) levels yielded 98.7% specificity, 90.5% sensitivity, 98.8% PPV, and 90.1% NPV for discriminating patients with PDAC from HRIs. CONCLUSIONS: TSP-2 is a highly specific diagnostic marker and an independent prognostic marker in patients with PDAC. A combined biomarker panel, including TSP-2 and CA19-9, may facilitate future PDAC screening.
BACKGROUND:Thrombospondin-2 (TSP-2) has been reported as an early diagnostic marker for pancreatic ductal adenocarcinoma (PDAC) in Caucasian populations. This study was designed to validateTSP-2 as a diagnostic marker in a large Taiwan cohort and to investigate the association of TSP-2 with the clinical outcomes of PDACpatients. METHODS: The serum TSP-2 levels in 263 PDACpatients and 230 high-risk individuals (HRIs) were measured via an enzyme-linked immunosorbent assay. The sensitivity, specificity, and accuracy of TSP-2 as a diagnostic marker to discriminating PDACpatients from HRIs and correlations between TSP-2 levels and prognosis of PDACpatients were analyzed. RESULTS: Serum TSP-2 levels were significantly higher in patients with PDAC (44.90 ± 40.70 ng/ml) than in the HRIs (17.52 ± 6.23 ng/ml). At a level of ≥ 29.8 ng/ml, TSP-2 exhibited 100% specificity, 55.9% sensitivity, 100% positive predictive value (PPV), and 66.5% negative predictive value (NPV) for discriminating PDACpatients from HRIs. The Cox regression analysis showed that higher serum TSP-2 levels were significantly associated with poor outcomes in PDACpatients (hazard ratio = 1.54, 95% confidence interval = 1.143-2.086, P = 0.005). Combining the carbohydrate antigen 19-9 (CA19-9) (cutoff value of 62.0 U/ml) and TSP-2 (cutoff value of 29.8 ng/ml) levels yielded 98.7% specificity, 90.5% sensitivity, 98.8% PPV, and 90.1% NPV for discriminating patients with PDAC from HRIs. CONCLUSIONS:TSP-2 is a highly specific diagnostic marker and an independent prognostic marker in patients with PDAC. A combined biomarker panel, including TSP-2 and CA19-9, may facilitate future PDAC screening.
Authors: Philip Zeuschner; Sebastian Hölters; Michael Stöckle; Barbara Seliger; Anja Mueller; Hagen S Bachmann; Viktor Grünwald; Daniel C Christoph; Arnulf Stenzl; Marc-Oliver Grimm; Fabian Brüning; Peter J Goebell; Marinela Augustin; Frederik Roos; Johanna Harde; Iris Benz-Rüd; Michael Staehler; Kerstin Junker Journal: Cancers (Basel) Date: 2021-05-25 Impact factor: 6.639
Authors: Tessa Y S Le Large; Laura L Meijer; Elisa Giovannetti; Geert Kazemier; Rosita Paleckyte; Lenka N C Boyd; Bart Kok; Thomas Wurdinger; Tim Schelfhorst; Sander R Piersma; Thang V Pham; Nicole C T van Grieken; Barbara M Zonderhuis; Freek Daams; Hanneke W M van Laarhoven; Maarten F Bijlsma; Connie R Jimenez Journal: Oncologist Date: 2020-01-14